Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-γ agonist, in obese diabetic rodent models

Journal of Pharmacological Sciences

Volumn 111, Issue 2, 2009, Pages 155-166

  Kanda, Shoichi ^a   Nakashima, Ryutaro ^a   Takahashi, Kanako ^a   Tanaka, Jun ^a   Ogawa, Junko ^a   Ogata, Tsuneaki ^a   Yachi, Makoto ^a   Araki, Kazushi ^a   Ohsumi, Jun ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Diabetes mellitus; Gene expression; Insulin resistance; Peroxisome proliferator activated receptor (PPAR) ; Thiazolidinedione

Indexed keywords

GLUCOSE; INSULIN; PIOGLITAZONE; PIRINIXIC ACID; RIVOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; FATTY ACID METABOLISM; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; INSULIN RESISTANCE; LIPOGENESIS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PEROXISOME; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 70350495216     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09084FP     Document Type: Article

References (34)

1. Yki-Järvinen H. Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet. 1994;343:91-95.
2. Reaven D. Insulin resistance, type 2 diabetes mellitus, and cardiovascular diseases: The end of beginning. Circulation. 2005;112:3030-3032. (Pubitemid 43113431)
3. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351: 1106-1118.
4. Semple RK, Chatterjee VKK, O'Rahilly S. PPARγ and human metabolic disease. J Clin Incest. 2006;116:581-589.
5. Tsuchida A, Yamauchi T, Kadowaki T. Nuclear receptors as targets for drug development: Molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor γ, CREB-binding protein, and adiponectin. J Pharmacol Sci. 2005;2:164-170. (Pubitemid 40410254)
6. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007;115:518-533. (Pubitemid 46184203)
7. Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W, Bonner-Weir S, et al. Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat. Diabetes. 1998;47:358-364. (Pubitemid 28104196)
8. Ishida H, Takizawa M, Ozawa S, Nakamichi Y, Yamaguchi S, Katsuta H, et al. Pioglitazone improves insulin secretory capacity and prevents the loss of β-cell mass in obese diabetic db/db mice: possible protection of β cells from oxidative stress. Metab. 2004;53:488-494. (Pubitemid 38419193)
9. Yajima K, Hirose H, Fujita H, Seto Y, Fujita H, Ukeda K, et al. Combination therapy with PPARγ and PPARα agonists increases glucose-stimulated insulin secretion in db/db mice. Am J Physiol Endocrinol Metab. 2003;284:E966-E971. (Pubitemid 36444032)
10. Serdy S, Abrahamson MJ. Durability of glycemic control: a feature of the thiazolidinediones. Diabetes Technol Ther. 2004; 6:179-189. (Pubitemid 38445743)
11. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443.
12. Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, Leonard T, et al. β-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes. 2001;50:1021-1029.
13. Vandewalle B, Moerman E, Lefebvre B, Defrance F, Gmyr V, Lukowiak B, et al. PPARγ-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets. Biochem Biophys Res Commun. 2008;366:1096-1101.
14. Libby P, Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-γ agonists. Am J Cardiol. 2007;99 Suppl:27B-40B. (Pubitemid 46239949)
15. Shimada K, Miyazaki T, Daida H. Adiponectin and atherosclerotic disease. Clin Chim Acta. 2004;344:1-12.
16. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:29-33.
17. Hug C, Lodish HF. The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr Opin Pharmacol. 2005;5:129-134. (Pubitemid 40378742)
18. Hockings PD, Changani KK, Saeed N, Reid DG, Birmingham J, O'Brien P, et al. Rapid reversal of hepatic steatosis, and reduction of muscle triglyceride, by rosiglitazone: MRI /S studies in Zucker fatty rats. Diabetes Obes Metab. 2003;5:234-243. (Pubitemid 36806127)
19. Souza SC, Yamamoto MT, Franciosa MD, Lien P, Greenberg AS. BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones. Diabetes. 1998;47:691-695. (Pubitemid 28160464)
20. Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA. A futile metabolic cycle activated in adipocytes by anti-diabetic agents. Nat Med. 2002;8:1122-1128.
21. Kramer JA, Blomme EA, Bunch RT, Davila JC, Jackson CJ, Jones PF, et al. Transcription profiling distinguishs dose-dependent effects in the livers of rats treated with clofibrate. Toxicol Pathol. 2003;31:417-431.
22. Edvardsson U, Alexandersson M, von Löwenhielm HB, Nyström AC, Ljung B, Nilsson F, et al. A proteome analysis of livers from obese (ob/ob) mice treated with the peroxisome proliferator WY14,643. Electrophoresis. 1999;20:935-942.
23. Yamazaki K, Kuromitsu J, Tanaka I. Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator-activated receptor α agonists. Biochem Biophys Res Commun. 2002;90:1114-1122. (Pubitemid 34687479)
24. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun. 2000;278:704-711.
25. Suzuki A, Yasuno T, Kojo H, Hirosumi J, Mutoh S, Notsu Y. Alteration in expression profiles of a series of diabetes-related genes in db/db mice following treatment with thiazolidinediones. Jpn J Pharmacol. 2000;84:113-123. (Pubitemid 30833880)
26. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, Mansfield TA, et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor γ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology. 2001;142:1269-1277.
27. Chaput E, Saladin R, Silvestre M, Edgar AD. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun. 2000;271:445-450. (Pubitemid 30444746)
28. Dana SL, Hoener PA, Bilakovics JM, Crombie DL, Ogilvie KM, Kauffman RF, et al. Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat. Matabolism. 2001;50:963-971.
29. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II potential mechanisms. Circulation. 2002;105:1861-1870. (Pubitemid 34408899)
30. Severson DL. Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes. Can J Phyisol Pharmacol. 2004;82:813-823. (Pubitemid 40223218)
31. Carley AN, Severson DL. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim Biophys Acta. 2005;1734:112-126.
32. Golfman LS, Wilson CR, Sharma S, Burgmaier M, Young ME, Guthrie PH, et al. Activation of PPARγ enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats. Am J Phsysiol Endocrinol Metab. 2005;289:E328-E336. (Pubitemid 41076636)
33. Nadal-Ginard B, Mahdavi V. Molecular basis of cardiac performance: Plasticity of the myocardium generated through protein isoform switches. J Clin Invest. 1989;84:1693-1700. (Pubitemid 20016170)
34. Netticadan T, Temsah RM, Kent A, Elimban V, Dhalla NS. Depressed levels of Ca2+-cycling proteins may underlie sarcoplasmic reticulum dysfunction in the diabetic heart. Diabetes. 2001;50:2133-2138. (Pubitemid 33643682)